Skip to main content
65°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
August 19, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
July 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 27, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Leadership Team Promotions
May 30, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
May 21, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
May 16, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 15, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
May 02, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 14, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
March 11, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
January 31, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
January 08, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
November 21, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
November 07, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
October 27, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
October 26, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
October 17, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
October 17, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
July 26, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
May 23, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
January 09, 2023
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
November 01, 2022
From
Monte Rosa Therapeutics, Inc.
Via
GlobeNewswire
Tickers
GLUE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.